This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Bristol-Myers Squibb And Meso Scale Discovery Enter Agreement To Develop Diagnostic Assays For Alzheimer’s Disease

Bristol-Myers Squibb Company (NYSE:BMY) and Meso Scale Discovery today announced they have entered an agreement to develop diagnostic assays that will measure cerebrospinal fluid biomarkers for use in Alzheimer’s disease research.

Under the terms of the agreement, the companies will develop these assays based on the Meso Scale Discovery ® MULTI-ARRAY technology platform. Meso Scale Discovery will commercialize the assays for Alzheimer’s disease research and drug development, and plans to release the assays in the second quarter of 2012. Terms of the agreement were not disclosed.

“The collaboration with Meso Scale Discovery demonstrates Bristol-Myers Squibb’s commitment to advancing the science of Alzheimer’s disease research,” said Jane Tiller, vice president, Global Clinical Research, Bristol-Myers Squibb. “These assays could provide the Alzheimer’s disease research community with an important tool to help advance understanding of this complex and devastating disease and may lead to advances in the diagnosis and treatment of Alzheimer’s disease.”

“This partnership fits perfectly into our mission of developing novel biomarkers tests for use in research and diagnostics,” said Jacob Wohlstadter, President and CEO of Meso Scale Discovery. “Bristol-Myers Squibb is a leader in the field of Alzheimer’s disease research and brings a clinical development perspective that pairs well with our experience in developing high-quality assays.”

About Alzheimer's disease

Alzheimer's disease is a progressive brain disease that impairs memory, interferes with thinking and ultimately destroys the ability of an individual to carry out simple tasks. The disease is a continuum, with damage to the brain starting long before the onset of dementia. Alzheimer's affects 24 million people worldwide and the prevalence is projected to significantly increase over the coming decades due to the aging population. While there are medicines available to help treat the symptoms of Alzheimer's disease, there remains a significant unmet medical need for therapies that slow or prevent the progression of underlying disease.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,528.03 -114.98 -0.69%
S&P 500 1,972.18 -16.69 -0.84%
NASDAQ 4,776.5080 -51.8170 -1.07%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs